BRIEF published on 11/13/2025 at 07:35, 1 month 2 days ago Dermapharm Maintains Stability Amid Portfolio Adjustments Growth And Earnings Branded Pharmaceuticals Dermapharm 2025 Financial Results Portfolio Restructuring
PRESS RELEASE published on 11/13/2025 at 07:30, 1 month 2 days ago Stable earnings despite portfolio adjustment - 2025 guidance confirmed, strong growth in branded pharmaceuticals Dermapharm Holding SE reports stable earnings despite portfolio adjustments in Q3 2025, confirms 2025 guidance and strong growth in branded pharmaceuticals Pharmaceuticals Growth Earnings Dermapharm Holding SE Portfolio Adjustment
BRIEF published on 08/26/2025 at 07:35, 3 months 20 days ago Dermapharm Reports Stable Business in H1 2025 and Q2 EBITDA Growth Financial Results EBITDA Growth Revenue Stability Branded Pharmaceuticals Dermapharm Performance
PRESS RELEASE published on 08/26/2025 at 07:30, 3 months 20 days ago Dermapharm confirms stable business development in H1 2025 and records EBITDA growth in Q2 versus prior-year quarter Dermapharm confirms stable business development in H1 2025 with EBITDA growth in Q2. Full-year guidance for 2025 reiterated. Branded pharmaceuticals main growth driver Revenue Pharmaceuticals EBITDA Growth Dermapharm H1 2025
BRIEF published on 08/12/2025 at 07:35, 4 months 3 days ago Dermapharm Holding SE Continues Growth in Q2 2025 Revenue Forecast EBITDA Growth Branded Pharmaceuticals Dermapharm Q2 2025 Performance
PRESS RELEASE published on 08/12/2025 at 07:30, 4 months 3 days ago Dermapharm Holding SE remains on projected growth trajectory in Q2 2025 Dermapharm Holding SE reports Q2 2025 results in line with expectations. Confirms full-year guidance of EUR 1,160–1,200 million revenue and EUR 322–332 million EBITDA Pharmaceuticals EBITDA Growth Dermapharm Holding SE Full-year Guidance Q2 2025 Results
BRIEF published on 06/26/2025 at 17:48, 5 months 18 days ago Dermapharm Holding SE Approves EUR 0.90 Dividend Per Share Sustainability Dividend AGM Financial Outlook Dermapharm
PRESS RELEASE published on 06/26/2025 at 17:43, 5 months 18 days ago Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.90 per share Dermapharm Holding SE's Annual General Meeting approves divident distribution of EUR 0.90 per share for 2024, confirms 2025 outlook and ratifies Board actions Annual General Meeting Financial Year 2024 Dividend Distribution Dermapharm Holding SE EUR 0.90 Per Share
BRIEF published on 05/15/2025 at 07:35, 7 months ago Dermapharm Holding SE Meets Q1 2025 Expectations, Reinforces Full-Year Forecast Revenue Growth Full-year Guidance EBITDA Decline Branded Pharmaceuticals Dermapharm Q1 2025
PRESS RELEASE published on 05/15/2025 at 07:30, 7 months ago Dermapharm Holding SE performs in line with projections in Q1 2025, confirms full-year guidance Dermapharm Holding SE reports Q1 2025 results in line with projections, confirming full-year guidance. Revenue increases by 1.2% year-on-year to EUR 302.4 million Adjusted EBITDA Revenue Growth Dermapharm Holding SE Full-year Guidance Q1 2025 Results
Published on 12/15/2025 at 15:00, 1 hour 8 minutes ago Kingfisher Reports Annual General Meeting Voting Results
Published on 12/15/2025 at 15:00, 1 hour 8 minutes ago Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Published on 12/15/2025 at 14:30, 1 hour 38 minutes ago Unusual Machines Congratulates Customers Selected for the Army's PBAS Tranche 1.1, Including Envision Technology and Strategic Logix
Published on 12/15/2025 at 14:00, 2 hours 8 minutes ago Dateline Delivers Further High-Grade Intercepts from North Pipe at Colosseum
Published on 12/15/2025 at 13:30, 2 hours 38 minutes ago Greenlane Announces Results of Annual Meeting of Stockholders, Canopy Growth Co Founder Bruce Linton Joins Greenlane's Board of Directors
Published on 12/15/2025 at 15:50, 17 minutes ago Original-Research: Cabka N.V. (von First Berlin Equity Research GmbH): Kaufen
Published on 12/15/2025 at 15:49, 18 minutes ago Mutares submits an irrevocable offer to acquire Venator Ultramarine Blue Pigments business from Venator France SAS
Published on 12/15/2025 at 15:45, 22 minutes ago Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 12/15/2025 at 15:44, 23 minutes ago Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 12/15/2025 at 15:43, 24 minutes ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 12/15/2025 at 11:50, 4 hours 17 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of November 30, 2025
Published on 12/12/2025 at 18:00, 2 days 22 hours ago Disclosure of trading in own shares between November 24th and November 28th, 2025
Published on 12/11/2025 at 08:30, 4 days 7 hours ago Edenred and Daimler Truck join forces to accelerate the rollout of charging infrastructure for electric trucks in Europe
